Williams CC - Search Results

1

Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older.

Simon GR, Extermann M, Chiappori A, Williams CC, Begum M, Kapoor R, Haura EB, Ismail-Khan R, Schell MJ, Antonia SJ, Bepler G. Simon GR, et al. Among authors: williams cc. Cancer. 2008 May 1;112(9):2021-9. doi: 10.1002/cncr.23360. Cancer. 2008. PMID: 18300255 Free article. Clinical Trial.

2

A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma.

Gray JE, Chiappori A, Williams CC, Tanvetyanon T, Haura EB, Creelan BC, Kim J, Boyle TA, Pinder-Schenck M, Khalil F, Altiok S, Devane R, Noyes D, Mediavilla-Varela M, Smilee R, Hopewell EL, Kelley L, Antonia SJ. Gray JE, et al. Among authors: williams cc. Cancer Immunol Immunother. 2018 Dec;67(12):1853-1862. doi: 10.1007/s00262-018-2236-7. Epub 2018 Sep 12. Cancer Immunol Immunother. 2018. PMID: 30209589 Free PMC article. Clinical Trial.

3

Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution.

Simon GR, Ruckdeschel JC, Williams C, Cantor A, Chiappori A, Rocha Lima CM, Antonia S, Haura E, Wagner H, Robinson L, Sommers E, Alberts M, Bepler G. Simon GR, et al. Cancer Control. 2003 Sep-Oct;10(5):388-95. doi: 10.1177/107327480301000506. Cancer Control. 2003. PMID: 14581894 Free article. Clinical Trial.

4

Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer.

Chiappori A, Simon G, Williams C, Haura E, Rocha-Lima C, Wagner H, Bepler G, Antonia S. Chiappori A, et al. Oncology. 2005;68(4-6):382-90. doi: 10.1159/000086979. Epub 2005 Jul 12. Oncology. 2005. PMID: 16020967 Review.

5

Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial.

Simon GR, Lush RM, Gump J, Tetteh L, Williams C, Cantor A, Antonia S, Garrett C, Rocha-Lima C, Fishman M, Sullivan DM, Munster PN. Simon GR, et al. Mol Cancer Ther. 2006 Aug;5(8):2130-7. doi: 10.1158/1535-7163.MCT-06-0034. Mol Cancer Ther. 2006. PMID: 16928835 Clinical Trial.

6

Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.

Simon G, Sharma A, Li X, Hazelton T, Walsh F, Williams C, Chiappori A, Haura E, Tanvetyanon T, Antonia S, Cantor A, Bepler G. Simon G, et al. J Clin Oncol. 2007 Jul 1;25(19):2741-6. doi: 10.1200/JCO.2006.08.2099. J Clin Oncol. 2007. PMID: 17602079 Clinical Trial.

7

Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.

Chiappori AA, Haura E, Rodriguez FA, Boulware D, Kapoor R, Neuger AM, Lush R, Padilla B, Burton M, Williams C, Simon G, Antonia S, Sullivan DM, Bepler G. Chiappori AA, et al. Clin Cancer Res. 2008 Mar 1;14(5):1464-9. doi: 10.1158/1078-0432.CCR-07-1508. Clin Cancer Res. 2008. PMID: 18316570 Clinical Trial.

8

Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer.

Bepler G, Sommers KE, Cantor A, Li X, Sharma A, Williams C, Chiappori A, Haura E, Antonia S, Tanvetyanon T, Simon G, Obasaju C, Robinson LA. Bepler G, et al. J Thorac Oncol. 2008 Oct;3(10):1112-8. doi: 10.1097/JTO.0b013e3181874936. J Thorac Oncol. 2008. PMID: 18827606 Free PMC article. Clinical Trial.

9

Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.

Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song L, Rawal B, Schell MJ, Bepler G. Haura EB, et al. J Clin Oncol. 2010 Mar 10;28(8):1387-94. doi: 10.1200/JCO.2009.25.4029. Epub 2010 Feb 8. J Clin Oncol. 2010. PMID: 20142592 Free PMC article. Clinical Trial.

10

Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer.

Bepler G, Dilling TJ, Wagner H, Hazelton T, Williams C, Chen DT, Greenberg H, Walsh F, Simon G, Tanvetyanon T, Chiappori A, Haura E, Stevens C. Bepler G, et al. J Thorac Oncol. 2011 Mar;6(3):553-8. doi: 10.1097/JTO.0b013e31820b8d88. J Thorac Oncol. 2011. PMID: 21289520 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

308 results

Search Page